Professor of Oncology- Mikhail Blagosklonny

Posted on March 11, 2017 By

Mikhail Blagosklonny is a scientist by profession. He is a professor of oncology, and his primary specialization is in cancer and aging. From an early age, he had a passion for medicine. After his High School graduation, Mikhail attended the First Pavlov State Medical University of St Peterburg. Mikhail graduated with a master’s degree in internal medicine and a Ph.D. in experimental medicine. His love for medicine, as well as his positive leadership traits, gave him an opportunity to serve as an associate professor at New York Medical College in Valhalla. Read more on Impact Journals.

Professor Mikhail has held other top position in different medical institutions including working as a Senior Scientist at Ordway Research Institute where he used to work for more than six years. In 2009 he joined Roswell Park Cancer Institute as a Professor of Oncology. At the Institute, he is responsible for teaching and also conducting researches on cancer and aging.

Mikhail has written several books on medical topics and more than 270 papers which have got more than 3000 citations which have given him an h-index of 83. He has been carrying out different studies which revolve around signal transduction, molecular biology, tumor suppressors, and oncogenes. Over the years Professor Mikhail has been developing new and unique plans that have made him one of top cancer and aging researchers in the world.

Mikhail Blasgosklonny has conducted one of the most famous studies, the role of TOR signaling in aging. In his studies, he mentions that cancer is caused by over developing of cells and that cancer is a sign of aging. He went ahead to propose the use of rapamycin on which can act as an anti-aging drug. In one of his articles, the professor of cancer demonstrates how rapamycin slows down cellular senescence which in turns reduces with age. He is also a Chief Editor who works with Oncotarget. Oncotarget is a journal of oncology that is published by Impact journal. The journal is free and is distributed on a weekly basis. Anyone in the world can access the Oncotarget journal. Mikhail edits on Cancer, Biology and Therapy, Autophagy, and Death and Differentiation.

Check Mikhail’s profile in LinkedIn


  1. Clarissa Brody says:

    We can be forgiven to see that most of the health challenges are not something that we actively get involved with. However failing to follow writers to be involved with the services will have to be a way to show support. Having the knowledge this is really good and I think we can create more scientist to help that way extensively.

Comments are closed.